Histamine, substance P and calcitonin gene-related peptide plasma concentration and pruritus in patients suffering from psoriasis

Dermatology and Psychosomatics

Volumn 5, Issue 2, 2004, Pages 73-78

  WisNicka B ^a   Szepietowski, J C ^a,b   Reich, A ^a   Orda, A ^b  

^a Dept Dermatol Venereol Allergol ^*  (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Neuropeptides; Pruritus; Psoriasis

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; HISTAMINE; SUBSTANCE P;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; HEALTH STATUS; HISTAMINE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PRURITUS; PSORIASIS; QUESTIONNAIRE; RADIOIMMUNOASSAY; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE; VISUAL ANALOG SCALE;

EID: 4344567345     PISSN: 14229196     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079211     Document Type: Article

References (52)

1. Anand P, Springail DR, Blank K: Neuropeptides in skin diseases: Increased VIP in eczema and psoriasis but not hyperhidrosis. Br J Dermatol 1991;124:547-549.
2. Arnold WP, van de Kerkhof PC: Topical capsaicyn in pruritic psoriasis. J Am Acad Dermatol 1994;31:135.
3. Bernhard JD: Nonrashes. 5. Atmokinesis: Pruritus provoked by contact with air. Cutis 1989;44:143-144.
4. Bischoff SC, Dahinden CA: Effect of nerve growth factor on the release of inflammatory mediators by mature human basophils. Blood 1992;79:2662-2669.
5. Caughley GH: Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 1988;244:133-137.
6. Chan J, Smoller BR, Raychauduri SP, Jiang WY, Farber EM: Intraepidermal nerve fiber expression of calcitonin gene-related peptide, vasoactive intestinal peptide and substance P in psoriasis. Arch Dermatol Res 1997;289:611-616.
7. Christophers E, Mrowietz U: Psoriasis; in Freedberg IM (ed): Fitzpatrick's Dermatology in General Medicine. New York, McGraw-Hill, 1999, pp 495-521.
8. Eady DJ: Neuropeptides in skin. Br J Dermatol 1993; 128:597-605.
9. Eady DJ, Johnston CF, Shaw C, Buchanan KD: Neuropeptides in psoriasis: An immunocytochemical and radioimmunoassay study. J Invest Dermatol 1991;96:434-438.
10. Ellis CN, Berberian B, Sulica VI, Dodd WA, Jarratt MT, Katz HI, Prawer S, Krueger G, Rex IH Jr, Wolf JE: A double-blind evaluation of topical capsaicin in pruritic psoriasis. J Acad Dermatol 1993;29:438-442.
11. Farber EM, Nall L: Psoriasis: A stress related disease. Cutis 1993;51:322-326.
12. Farber EM, Nall L: Epidemiology: Natural history and genetics; in Roenigk HH Jr, Maibach HI (eds): Psoriasis. New York, Marcel Dekker, 1998, pp 107-157.
13. Farber EM, Nickoloff BJ, Recht B, Fraki JE: Stress, symmetry and psoriasis: Possible role of neuropeptides. J Am Acad Dermatol 1986;14:305-311.
14. Fleischer AB Jr: The clinical manifestation of itching. New York, Parthenon, 2000.
15. Fredriksson T, Petersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-241.
16. Ginsburg IH: Psychological and psychophysiological aspect of psoriasis. Dermatol Clin 1995;13:793-804.
17. Gittlen SD, Schulman ES, Maddrey WC: Raised histamine concentrations in chronic cholestatic liver disease. Gut 1990;31:96-99.
18. Gliński W, Brodecka H, Glińska-Ferenz M: Increased concentration of beta-endorphin in sera of patients with psoriasis and other inflammatory dermatoses. Br J Dermatol 1994;131:260-264.
19. Gupta MA, Gupta AK: The psoriasis life stress inventory: A preliminary index of psoriasis related stress. Acta Derm Venereol 1995;75:240-243.
20. Gupta MA, Gupta AK, Kirkby S, Weiner HK, Mace TM, Schork NJ, Johnson EH, Ellis CN, Voorhees JJ: Pruritus in psoriasis. A prospective study of some psychiatric and dermatologic correlates. Arch Dermatol 1988;124:1052-1057.
21. Hägermark Ö, Hökfelt T, Pemau B: Flare and itch induced by substance P in human skin. J Invest Dermatol 1978;71:233-235.
22. Harvima RJ, Haapanen L, Ackermann L, Naukkarinen A, Harvima RJ, Horsmanheimo M: Decreased chymase activity is associated with increased levels of protease inhibitors in mast cells of psoriatic lesions. Acta Derm Venereol 1999;79:98-104.
23. He Y, Ding G, Wang X, Zhu T, Fan S: Calcitonin generelated peptide in Langerhans cells in psoriatic plaque lesions. Chin Med J 2000;113:747-751.
24. Jiang WY, Raychaudhuri SP, Farber EM: Double-labeled immunofluorescence study of cutaneous nerves in psoriasis. Int J Dermatol 1998;37:572-574.
25. Mettang T, Fritz P, Weber J, Machleidt C, Hubel E, Kuhlmann U: Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 1990;34:136-141.
26. Mozzanica N, Cattaneo A, Vignati G, Finzi A: Plasma neuropeptide levels in psoriasis. Acta Derm Venereol 1994;186:67-68.
27. Nakamura M, Toyoda M, Morohashi M: Pruritogenic mediators in psoriasis: Comparative evaluation of itch-associated cutaneous factors. Br J Dermatol 2003;149:718-730.
28. Naukkarinen A, Nickoloff BJ, Farber EM: Quantification of cutaneous sensory nerves and their substance P content in psoriasis. J Invest Dermatol 1989;92:126-129.
29. Pacan P, Szepietowski J: Influence of stress on the exacerbation of psoriasis. Dermatol Klin Zabieg 2001; 3(suppl 1):112.
30. Peharda V, Gruber F, Kastelan M, Brajac I, Cabrijan L: Pruritus an important symptom of internal diseases. Acta Dermatoven APA 2000;9:92-104.
31. Pincelli C, Fantini F, Romualdi P, Sevignani C, Lesa G, Benassi L, Gianetti A: Substance P is diminished and vasoactive intestinal peptide is augmented in psoriatic lesions and these peptides exert disparate effects on the proliferation of cultured human keratinocytes. J Invest Dermatol 1992;98:421-427.
32. Reich A, Szepietowski J: The treatment modalities in the skin pruritus. Derm Kosmetyczna 2002;4:251-256.
33. Reich A, Szepietowski JC, WiÉnicka B, Pacan P: Does stress influence itching in psoriatic patients? Dermatol Psychosom 2003;4:151-155.
34. Reimann S, Luger T, Metze D: Topical administration of capsaicyn in dermatology for treatment of itching and pain. Hautarzt 2000;51:164-172.
35. Roenigk HH, Epstein E, Maibach HI: Skin manifestations of psoriasis and eczematous psoriasis: Maturation; in Roenigk HH, Maibach HI (ed): Psoriasis. New York, Marcel Dekker, 1998, pp 3-12.
36. Stern R, Wu J: Psoriasis; in Arndt KA, Le Boit PE, Robinson JK, (eds): Cutaneous medicine and surgery. Philadelphia, WB Saunders, 1996, pp 295-321.
37. Szepietowski J: Selected elements of pruritus in hemodialysis patients. Med Sci Monit 1996;2:343-347.
38. Szepietowski J: Pruritus and its pathogenesis. Dermatol Klin Zabieg 1999;1:45-48.
39. Szepietowski JC, Schwartz RA: Uremic pruritus. Int J Dermatol 1998;37:247-253.
40. Szepietowski J, Thepen T, van Vloten WA, Szepietowski T: Pruritus and mast cells proliferation in the skin of haemodialysis patients. Inflamm Res 1995; 44:84-85.
41. Szepietowski JC, Sikora M, Pacholek T, Dmochowska A: Clinical evaluation of the Self-Administered Psoriasis Area and Severity Index (SAPASI). Acta Dermatoven APA 2001;10:79-83.
42. Szepietowski JC, Morita A, Tsuji T: Ultraviolet B induces mast cell apoptosis: A hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses 2002;58:167-170.
43. Szepietowski JC, Reich A, Wiśnicka B: Itching in patients suffering from psoriasis. Acta Dermatovenereol Croat 2002;10:221-226.
44. Toruniowa B, Jabłoska S: Mast cells in the initial stages of psoriasis. Arch Dermatol Res 1988;280:189-193.
45. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z: Itch: Scratching more than the surface. Q J Med 2003;96: 7-26.
46. Van de Kerkhof PC: Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol 2001;26:356-361.
47. Van de Kerkhof PC, de Hoop D, de Korte J, Kuipers MV: Scalp psoriasis, clinical presentations and therapeutic management. Dermatology 1998;197:326-334.
48. Van de Kerkhof PC, de Hoop D, de Korte J, Cobelens SA, Kuipers MV: Patients complaints and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-298.
49. Wahlgren CF, Ekblom A, Hägermark Ö: Some aspects of the experimental induction and measurement of itch. Acta Derm Venereol 1989;69:185-189.
50. Wa̧sik F, Szepietowski J, Szepietowski T, Weyde W: Relief of uraemic pruritus after balneological therapy with a bath oil containing polidocanol (Balneum Hermal). An open clinical study. J Dermatol Treat 1996;7:231-233.
51. Wiénicka B, Reich A, Szepietowski JC: Does psoriasis itch? Medipress Dermatol 2003;1:22-26.
52. Yosipovitch G, Goon A, Wee J, Chan YW, Goh CL: The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis. Br J Dermatol 2000;143:969-973.